Type 2 Diabetes

The t:Slim X2 insulin pump is both compatible with outside therapy systems, and capable of delivering insulin on its own.

The CAROLINA cardiovascular safety study found that linagliptin was non-inferior to glimepiride in time to a composite cardiovascular endpoint.

Current smokers with type 1 diabetes had higher A1c values and greater risk of microvascular complications compared with former and never smokers, according to results of a new study.

Authors of a new study found that patients who develop diabetes later in life have a higher risk of cardiovascular disease.

Is the number of CV health measures associated with similar risk reduction among patients with higher T2DM risk or lower risk? New study sheds light.

Have a quick look at 3 top mobile apps that can help your patients better manage a range of thyroid conditions.

Is DiaRem or Advanced DiaRem better for predicting diabetes remission post-bariatric surgery? Authors of a recent study sought to find out. 

Investigators found the first evidence of a decline in type 1 diabetes incidence following implementation of the oral rotavirus vaccine into a routine immunization schedule.

Statins are already a common therapy among patients with type 2 diabetes. Its cholesterol-lowering benefits may help retain patient vision longer.

A new study found a strong link between high triglyceride levels and poor glucose control in T2DM patients who are taking insulin. Click through our slideshow to get more details. 

We see ~30 patients/day; some wait up to 90-days to be seen; many private endo practices are closed to new patients. The question is not overstated. 

The investigative SGLT1/2 dual inhibitor is scheduled to be considered for marketing approval by mid-March.

Take 5 with a quick quiz on a variety of diabetes treatment topics.

How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell. 

Once one of the country healthcare system's greatest successes, CVD and related mortality is rising again. What's its true cause?

Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.

The leading etiologies for chronic-liver-disease-related-deaths over the last decade can be explained by NAFLD and alcoholic liver disease.

Highlights include an online diabetes prevention program; sweetened drinks pose greater diabetes risk; and the link between night shifts and T2DM.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.